Citation Tools
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioning
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioning